| Schedule of financial assets and liabilities measured at fair value on a recurring basis |
The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): | | | | | | | | | | | | | | | Fair Value Measurements as of June 30, 2025 using: | | | Quoted Prices in | | Significant Other | | Significant | | | | | | Active Markets for | | Observable | | Unobservable | | | | | | Identical Assets | | Inputs | | Inputs | | | | | | (Level 1) | | (Level 2) | | (Level 3) | | Total | Assets: | | | | | | | | | | | | | Cash equivalents: | | | | | | | | | | | | | Money market funds | | $ | 42,134 | | $ | — | | $ | — | | $ | 42,134 | U.S. treasury bills | | | 25,934 | | | — | | | — | | | 25,934 | Total cash equivalents | | | 68,068 | | | — | | | — | | | 68,068 | Investment in equity securities | | | 8,801 | | | — | | | — | | | 8,801 | Exarafenib milestone asset | | | — | | | — | | | 3,402 | | | 3,402 | Castle Creek PRV Interest (Note 5) | | | — | | | — | | | — | | | — | Castle Creek warrants (Note 5) | | | — | | | — | | | 609 | | | 609 | Total financial assets | | $ | 76,869 | | $ | — | | $ | 4,011 | | $ | 80,880 | Liabilities: | | | | | | | | | | | | | Exarafenib milestone contingent consideration (Note 4) | | $ | — | | $ | — | | $ | 3,402 | | $ | 3,402 | Total financial liabilities | | $ | — | | $ | — | | $ | 3,402 | | $ | 3,402 |
| | | | | | | | | | | | | | | Fair Value Measurements as of December 31, 2024 using: | | | Quoted Prices in | | Significant Other | | Significant | | | | | | Active Markets for | | Observable | | Unobservable | | | | | | Identical Assets | | Inputs | | Inputs | | | | | | (Level 1) | | (Level 2) | | (Level 3) | | Total | Assets: | | | | | | | | | | | | | Cash equivalents: | | | | | | | | | | | | | Money market funds | | $ | 72,304 | | $ | — | | $ | — | | $ | 72,304 | U.S. treasury bills | | | 20,367 | | | — | | | — | | | 20,367 | Total cash equivalents | | | 92,671 | | | — | | | — | | | 92,671 | Investment in equity securities | | | 3,529 | | | — | | | — | | | 3,529 | Exarafenib milestone asset (Note 4) | | | — | | | — | | | 3,214 | | | 3,214 | Total financial assets | | $ | 96,200 | | $ | — | | $ | 3,214 | | $ | 99,414 | Liabilities: | | | | | | | | | | | | | Exarafenib milestone contingent consideration (Note 4) | | $ | — | | $ | — | | $ | 3,214 | | $ | 3,214 | Total financial liabilities | | $ | — | | $ | — | | $ | 3,214 | | $ | 3,214 |
|